Literature DB >> 23031329

Increased ADAMTS13 activity in patients with venous thromboembolism.

Bruna M Mazetto1, Fernanda L Orsi, Aline Barnabé, Erich V De Paula, Mariane C Flores-Nascimento, Joyce M Annichino-Bizzacchi.   

Abstract

Increased levels of inflammatory markers and clotting factors have been related to the pathogenesis and prognosis of venous thromboembolism. In particular, the imbalance between VWF and ADAMTS13 has been described in patients with arterial thrombosis. In this study, 77 patients with previous VTE and 77 matched controls were selected for the evaluation of the inflammatory markers, FVW, ADAMTS 13 and D-dimer. The presences of post-thrombotic syndrome and residual vein obstruction were also assessed in patients. Serum levels of TNF-α and IL-6 were significantly increased in patients compared to controls (median=2.25 vs 1.59 pg/mL, P ≤ 0.001; 1.16 vs 0.98 pg/ml, P=0.013, respectively). Plasma levels and activity of VWF (median=150.25 vs 95.39 U/dL, P ≤ 0.001; 145.26% vs 92.39%, P ≤ 0.001) and ADAMTS 13 (median=1088.84 vs 950.80 ng/mL, P ≤ 0.001; 96.03 vs 83.64%, P ≤ 0.001) were also higher in patients. We further analysed the subgroups of patients with higher risk for VTE recurrence or VTE sequelae, defined as the presence of high D-dimer levels, RVO or PTS. All inflammatory markers were significantly higher in patients with increased D-dimer. The presence of PTS or RVO was not associated with higher inflammatory or coagulation parameters. The increased levels of inflammatory markers and VWF may suggest that there is a persistence of inflammatory activity in patients even at long periods after the VTE episode. In this context, it may be postulated that increased levels of ADAMTS13 could represent a compensatory mechanism against persistently increased levels of VWF. Moreover, increased inflammatory activity was associated with increased D-dimer levels, thus it is possible that this inflammatory activity may also be related to the risk of VTE recurrence.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23031329     DOI: 10.1016/j.thromres.2012.09.009

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.

Authors:  Michael Newnham; Kieron South; Marta Bleda; William R Auger; Joan A Barberà; Harm Bogaard; Katherine Bunclark; John E Cannon; Marion Delcroix; Charaka Hadinnapola; Luke S Howard; David Jenkins; Eckhard Mayer; Choo Ng; Christopher J Rhodes; Nicholas Screaton; Karen Sheares; Michael A Simpson; Mark Southwood; Li Su; Dolores Taboada; Matthew Traylor; Richard C Trembath; Sofia S Villar; Martin R Wilkins; John Wharton; Stefan Gräf; Joanna Pepke-Zaba; Michael Laffan; David A Lane; Nicholas W Morrell; Mark Toshner
Journal:  Eur Respir J       Date:  2019-03-28       Impact factor: 16.671

2.  The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.

Authors:  Hanna L Obermeier; Julia Riedl; Cihan Ay; Silvia Koder; Peter Quehenberger; Rupert Bartsch; Alexandra Kaider; Christoph C Zielinski; Ingrid Pabinger
Journal:  Res Pract Thromb Haemost       Date:  2019-05-06

3.  A Single Synonymous Variant (c.354G>A [p.P118P]) in ADAMTS13 Confers Enhanced Specific Activity.

Authors:  Ryan Hunt; Gaya Hettiarachchi; Upendra Katneni; Nancy Hernandez; David Holcomb; Jacob Kames; Redab Alnifaidy; Brian Lin; Nobuko Hamasaki-Katagiri; Aaron Wesley; Tal Kafri; Christina Morris; Laura Bouché; Maria Panico; Tal Schiller; Juan Ibla; Haim Bar; Amra Ismail; Howard Morris; Anton Komar; Chava Kimchi-Sarfaty
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

4.  Circulating ADAMTS13 Levels Are Associated with an Increased Occurrence of Obstructive Sleep Apnea.

Authors:  Mengling Huang; Sheng Liu; Shuang Liu; Wanwan Wen; Yu Ning; Yifan Jia; Yunxiao Yang; Xiaolu Jiao; Weiping Zheng; Ming Zhang
Journal:  Dis Markers       Date:  2022-03-29       Impact factor: 3.434

5.  Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.

Authors:  Zixiang Ye; Jingang Zheng
Journal:  Front Genet       Date:  2021-07-01       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.